Literature DB >> 10450518

Colitis in transgenic and knockout animals as models of human inflammatory bowel disease.

A K Bhan1, E Mizoguchi, R N Smith, A Mizoguchi.   

Abstract

Spontaneous colitis in knockout (KO) and transgenic rodents provides experimental models to study the development of mucosal inflammation and inflammatory bowel disease (Crohn's disease and ulcerative colitis). Genetic and environmental factors, particularly the normal enteric flora, are important factors in the development of mucosal inflammation. The normal mucosal homeostasis is disrupted when there is either cytokine imbalance, abrogation of oral tolerance, alteration of epithelial barrier and function or loss of immunoregulatory cells. Some but not all immunodeficiencies, in the appropriate setting, lead to colitis. CD4+ T cells have been identified as the pathogenic T cells in colitis, which mediate inflammation by either the Th1 or the Th2 pathway. The Th1 pathway dominates most colitis models and in Crohn's disease. In contrast, the colitis in TCR alpha KO mice shares many features of ulcerative colitis including the dominance of Th2 pathway in colonic inflammation. A major benefit of these models is in the development of therapeutic strategies for the treatment of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450518     DOI: 10.1111/j.1600-065x.1999.tb01316.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  37 in total

1.  Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease.

Authors:  M M Kosiewicz; C C Nast; A Krishnan; J Rivera-Nieves; C A Moskaluk; S Matsumoto; K Kozaiwa; F Cominelli
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease.

Authors:  S Dionne; S Laberge; C Deslandres; E G Seidman
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

3.  Appendix is a priming site in the development of ulcerative colitis.

Authors:  Mitsunobu Matsushita; Hiroshi Takakuwa; Yuji Matsubayashi; Akiyoshi Nishio; Susumu Ikehara; Kazuichi Okazaki
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

4.  Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?

Authors:  T T Pizarro; S A De La Rue; F Cominelli
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 5.  Layers of mutualism with commensal bacteria protect us from intestinal inflammation.

Authors:  C Mueller; A J Macpherson
Journal:  Gut       Date:  2006-02       Impact factor: 23.059

6.  Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.

Authors:  A Grabig; D Paclik; C Guzy; A Dankof; D C Baumgart; J Erckenbrecht; B Raupach; U Sonnenborn; J Eckert; R R Schumann; B Wiedenmann; A U Dignass; A Sturm
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 7.  Probiotics for the treatment of inflammatory bowel disease.

Authors:  Ganesh R Veerappan; John Betteridge; Patrick E Young
Journal:  Curr Gastroenterol Rep       Date:  2012-08

8.  Visualization of IL-22-expressing Lymphocytes Using Reporter Mice.

Authors:  Wei Shen; Wenqing Li; Julie A Hixon; Caroline Andrews; Scott K Durum
Journal:  J Vis Exp       Date:  2017-01-25       Impact factor: 1.355

9.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Gut microbiota-dependent modulation of innate immunity and lymph node remodeling affects cardiac allograft outcomes.

Authors:  Jonathan S Bromberg; Lauren Hittle; Yanbao Xiong; Vikas Saxena; Eoghan M Smyth; Lushen Li; Tianshu Zhang; Chelsea Wagner; W Florian Fricke; Thomas Simon; Colin C Brinkman; Emmanuel F Mongodin
Journal:  JCI Insight       Date:  2018-10-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.